Compare JAZZ & MOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | MOH |
|---|---|---|
| Founded | 2003 | 1980 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.9B |
| IPO Year | 2007 | 2003 |
| Metric | JAZZ | MOH |
|---|---|---|
| Price | $162.98 | $128.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 13 |
| Target Price | $207.19 | ★ $210.92 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 02-24-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.92 |
| Revenue | $4,157,832,999.00 | ★ $45,426,000,000.00 |
| Revenue This Year | $6.05 | $15.23 |
| Revenue Next Year | $6.23 | $4.17 |
| P/E Ratio | ★ N/A | $19.83 |
| Revenue Growth | 4.14 | ★ 15.99 |
| 52 Week Low | $95.49 | $133.40 |
| 52 Week High | $182.99 | $359.97 |
| Indicator | JAZZ | MOH |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 21.47 |
| Support Level | $162.24 | $176.00 |
| Resistance Level | $168.47 | $185.40 |
| Average True Range (ATR) | 4.02 | 6.94 |
| MACD | -0.39 | -5.81 |
| Stochastic Oscillator | 36.31 | 3.33 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Molina provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in just four states—California, New York, Texas, and Washington—account for over half of its enrollees.